Northern Trust Corp Theseus Pharmaceuticals, Inc. Transaction History

Northern Trust Corp

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$2.12 - $4.18 $5,819 - $11,474	-2,745 Reduced 1.74%	154,580 $626,000
Q3 2023 Nov 13, 2023	SELL	$2.66 - $10.04 $18,061 - $68,171	-6,790 Reduced 4.14%	157,325 $423,000
Q2 2023 Aug 11, 2023	BUY	$7.28 - $11.82 $223,168 - $362,342	30,655 Added 22.97%	164,115 $1.53 Million
Q1 2023 May 15, 2023	BUY	$5.21 - $14.05 $828 - $2,233	159 Added 0.12%	133,460 $1.19 Million
Q4 2022 Feb 13, 2023	SELL	$4.69 - $8.36 $1,191 - $2,123	-254 Reduced 0.19%	133,301 $663,000

Q3 2022 Nov 14, 2022	BUY	$5.7 - $8.68 $31,321 - $47,696	5,495 Added 4.29%	133,555 $775,000
Q2 2022 Aug 12, 2022	BUY	$5.04 - $14.05 $155,841 - $434,440	30,921 Added 31.83%	128,060 $708,000
Q1 2022 May 13, 2022	BUY	$8.75 - $14.51 $2,231 - $3,700	255 Added 0.26%	97,139 $1.12 Million
Q4 2021 Feb 08, 2022	BUY	$8.98 - $20.09 $870,018 - $1.95 Million	96,884 New	96,884 $1.23 Million

1.06M

Ticker THRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,713,400
Description
Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also ...

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

Stay updated on Northern Trust Corp with notifications on news.